Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Bachem (BANB.SW) is a drug manufacturers - specialty & generic company based in Bubendorf, Switzerland. In Q4 2025, it reported revenue of $432.00M.
BachemSwiss pure-play peptide CDMO; largest globally. CHF ~400M capex 2024 to 2025 across Bubendorf, Vista, and Torrance to expand solid-phase peptide synthesis capacity for GLP-1 demand.
H1 2006-H2 2025
H1 2016-H2 2025
H1 2016-H2 2025
Bachem (BANB.SW) is a Drug Manufacturers - Specialty & Generic company. Swiss pure-play peptide CDMO; largest globally. CHF ~400M capex 2024 to 2025 across Bubendorf, Vista, and Torrance to expand solid-phase peptide synthesis capacity for GLP-1 demand. It was founded in 1971, is headquartered in Bubendorf, Switzerland and employs about 2,000 people.
Track Bachem's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 24, 2026.
Sterling groups Bachem in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Bachem, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.